Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a non-neoplastic, age-related enlargement of the prostate gland in intact male dogs, characterized by hyperplasia of both glandular and stromal elements. It is the most common prostatic disorder in dogs, with a prevalence exceeding 80% in intact males over 6 years of age. The condition results from the cumulative effects of androgens, particularly dihydrotestosterone (DHT), on prostatic tissue, leading to an increase in gland size and weight. BPH is typically a diffuse, symmetrical enlargement that may cause clinical signs related to compression of the urethra, colon, or pelvic canal. While BPH is considered a benign condition, it can predispose to secondary complications such as prostatitis, prostatic cysts, and urinary tract infections. Surgical intervention is rarely required for uncomplicated BPH, but may be indicated for severe clinical signs, failure of medical management, or when complications such as prostatic abscessation or cyst formation occur. The condition is primarily managed medically with castration or anti-androgen therapy, but surgical options such as castration, prostatic omentalization, or partial prostatectomy may be considered in specific cases.

The primary etiology of benign prostatic hyperplasia is the age-related hormonal imbalance in intact male dogs, specifically the progressive increase in the ratio of estrogen to androgen within the prostatic tissue. Testosterone, secreted by the testes, is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha-reductase within prostatic stromal cells. DHT binds to androgen receptors in the nuclei of prostatic epithelial and stromal cells, stimulating DNA synthesis and cellular proliferation. Over time, the accumulation of DHT leads to hyperplasia of both glandular acini and stromal smooth muscle. Estrogen, produced in small amounts by the testes and peripherally from androgens, acts synergistically with DHT to induce squamous metaplasia of the prostatic epithelium and contribute to stromal proliferation. The exact molecular mechanisms involve upregulation of growth factors such as fibroblast growth factor (FGF) and epidermal growth factor (EGF), which promote cellular division. Additionally, chronic inflammation and oxidative stress may play a role in the progression of hyperplasia. Genetic predisposition may also influence the susceptibility to BPH, as certain breeds appear to be overrepresented. Iatrogenic causes are rare but can include exogenous androgen administration. The condition is exclusively seen in intact males, as castration leads to rapid involution of the prostate due to the withdrawal of androgens.

Benign prostatic hyperplasia is a common condition in intact male dogs, with prevalence increasing with age. Studies report that BPH is present in over 80% of intact male dogs older than 6 years, and nearly 100% of those older than 9 years. There is no breed predilection, but large-breed dogs may present with more severe clinical signs due to a larger prostate and greater compression of surrounding structures. Working dogs, such as German Shepherds, Labrador Retrievers, and Golden Retrievers, are often diagnosed because of their active lifestyle and the impact of urinary or fecal dysfunction on performance. The condition is rare in cats, with only sporadic reports, likely due to anatomical and hormonal differences. BPH is exclusively a disease of intact males; castrated dogs do not develop BPH. The incidence of clinical signs requiring intervention is lower than the histological prevalence, with only about 10-20% of affected dogs showing clinical signs. The economic impact is significant due to diagnostic workup and management, particularly in breeding animals where castration is not desired.

The pathophysiology of benign prostatic hyperplasia involves a complex interplay of hormonal, cellular, and molecular events. In intact male dogs, testosterone is secreted by the testes and converted to DHT in the prostate by 5-alpha-reductase. DHT binds to androgen receptors, activating transcription of genes that promote cellular proliferation and inhibit apoptosis. This leads to hyperplasia of both the glandular epithelium and the stromal fibromuscular tissue. The prostate enlarges symmetrically, often doubling or tripling in size. The enlarged prostate compresses the urethra, causing partial obstruction and leading to dysuria, stranguria, and urinary retention. Compression of the colon can result in tenesmus and constipation. The increased size may also impinge on the pelvic canal, causing discomfort and gait abnormalities. Histologically, BPH is characterized by an increased number of acini, papillary projections into the acinar lumen, and stromal proliferation. The glandular epithelium may become cystic, and there is often an inflammatory component. The condition is progressive, and without treatment, the prostate continues to enlarge, increasing the risk of secondary complications such as prostatitis, abscessation, and cyst formation. The systemic effects are generally minimal, but chronic urinary obstruction can lead to post-renal azotemia and electrolyte imbalances.

The primary predisposing factor for benign prostatic hyperplasia is intact male status and advancing age. The condition is directly related to the presence of testicular androgens, and castration prevents its development. Breed may influence the severity of clinical signs, with large-breed dogs more likely to exhibit significant urinary and fecal dysfunction due to the larger size of the prostate and its impact on surrounding structures. Obesity may exacerbate clinical signs by increasing intra-abdominal pressure and compressing the pelvic canal. Concurrent conditions such as prostatitis or prostatic cysts can complicate BPH and lead to more severe clinical signs. Genetic factors may play a role, as some lines of dogs appear to have a higher incidence. Environmental factors such as diet and exercise are not well-established but may influence overall health and the severity of clinical signs. The use of exogenous androgens or anabolic steroids can induce BPH in castrated dogs, although this is rare. Finally, the presence of other urogenital diseases, such as urethral sphincter mechanism incompetence, may predispose to urinary tract infections, which can exacerbate prostatic inflammation.

Clinical signs of benign prostatic hyperplasia are related to the enlargement of the prostate and its compression of adjacent structures. The most common signs include dysuria, stranguria, hematuria, and recurrent urinary tract infections. Dogs may also exhibit tenesmus, constipation, and ribbon-like stools due to colonic compression. In some cases, a palpable abdominal mass may be detected on physical examination. The prostate is typically symmetrically enlarged, smooth, and non-painful on rectal palpation. As the condition progresses, dogs may develop urinary incontinence, particularly if there is associated urethral sphincter dysfunction. Systemic signs such as fever, lethargy, and anorexia are uncommon unless secondary prostatitis or abscessation occurs. In severe cases, prostatic cysts may rupture, leading to peritonitis and acute abdomen. The severity of clinical signs does not always correlate with the size of the prostate, as some dogs with marked enlargement remain asymptomatic. Neurological signs are rare but can occur if the prostate compresses the lumbosacral plexus. The onset of signs is usually gradual, and owners may notice a progressive decline in urinary and fecal function.

Differential diagnoses for benign prostatic hyperplasia include prostatitis, prostatic abscess, prostatic cysts, prostatic neoplasia (adenocarcinoma), and other causes of lower urinary tract disease. Prostatitis is characterized by fever, lethargy, and a painful prostate on palpation, with systemic signs of infection. Prostatic abscesses present with acute onset of severe pain, fever, and often a fluctuant prostate on palpation; imaging may reveal cavitary lesions. Prostatic cysts can be paraprostatic or prostatic retention cysts, often associated with BPH, and may cause similar clinical signs. Prostatic adenocarcinoma is a malignant tumor that is highly invasive and metastatic, often presenting with a firm, irregular prostate, and may cause bone pain or lameness due to metastasis. Other differentials include urethral obstruction from urolithiasis, urethral stricture, or neoplasia of the urethra or bladder. Chronic urinary tract infections can cause similar signs, and a urinalysis and culture are essential. Additionally, colonic diseases such as constipation or megacolon should be considered. Diagnostic imaging and biopsy are crucial to differentiate these conditions.

The diagnostic algorithm for benign prostatic hyperplasia begins with a thorough history and physical examination, including digital rectal palpation of the prostate to assess size, symmetry, and consistency. A complete blood count, serum biochemistry, and urinalysis with culture are performed to rule out infection and assess renal function. Imaging is essential: abdominal radiographs may show an enlarged prostate, but ultrasonography is the preferred modality to evaluate prostatic size, echotexture, and the presence of cysts or abscesses. Ultrasonography can also guide fine-needle aspiration or biopsy. If neoplasia is suspected, thoracic radiographs and abdominal CT are recommended to screen for metastasis. Prostatic fluid evaluation via ejaculation or prostatic wash can be performed to assess for inflammation or infection. In cases where the diagnosis is uncertain, prostatic biopsy (ultrasound-guided or surgical) is indicated. Advanced imaging such as MRI may be used to evaluate the extent of disease and involvement of surrounding tissues. The diagnostic workup should also include assessment of the urinary tract for concurrent conditions such as urolithiasis or urethral obstruction. A stepwise approach ensures accurate diagnosis and guides treatment decisions.

Laboratory findings in benign prostatic hyperplasia are often unremarkable unless secondary complications are present. Complete blood count may show leukocytosis with a left shift if prostatitis or abscessation is present. Serum biochemistry may reveal elevated blood urea nitrogen and creatinine if urinary obstruction has occurred, leading to post-renal azotemia. Urinalysis may show hematuria, pyuria, and bacteriuria if a urinary tract infection is present; urine culture is essential to guide antimicrobial therapy. Prostatic fluid evaluation via ejaculation or prostatic wash may show increased numbers of neutrophils and bacteria in cases of prostatitis. In uncomplicated BPH, prostatic fluid is typically normal. Coagulation profile is usually within normal limits, but is recommended prior to surgical intervention. Inflammatory biomarkers such as C-reactive protein may be elevated in cases of prostatitis. Hormonal assays for testosterone and estrogen are not routinely performed but may be useful in research settings. Overall, laboratory findings are nonspecific and must be interpreted in conjunction with imaging and clinical signs.

Imaging plays a crucial role in the diagnosis and management of benign prostatic hyperplasia. Abdominal radiographs may reveal an enlarged prostate, which appears as a soft tissue mass in the caudal abdomen, often causing dorsal displacement of the colon and cranial displacement of the bladder. However, radiographs are not sensitive for detecting subtle changes. Ultrasonography is the primary imaging modality, allowing accurate measurement of prostatic dimensions, assessment of symmetry, and evaluation of echotexture. In BPH, the prostate is typically symmetrically enlarged with a homogeneous or slightly heterogeneous echotexture, and there may be small cystic areas. Ultrasonography can also detect prostatic cysts, abscesses, and mineralization, and can guide fine-needle aspiration or biopsy. Contrast-enhanced ultrasound may provide additional information on vascularity. Computed tomography (CT) provides detailed cross-sectional imaging and is useful for surgical planning, particularly in cases of prostatic neoplasia or complex cysts. CT can accurately assess the extent of disease and involvement of regional lymph nodes. Magnetic resonance imaging (MRI) offers superior soft tissue contrast and is valuable for evaluating the prostatic capsule and surrounding structures. Urethrography or cystography may be performed to assess urethral compression or obstruction. In cases of suspected metastasis, thoracic radiographs or CT are indicated. Overall, ultrasonography is the most practical and widely used imaging modality for BPH.

Cytological and histopathological evaluation is essential for definitive diagnosis of benign prostatic hyperplasia and to rule out neoplasia. Fine-needle aspiration of the prostate can be performed percutaneously under ultrasound guidance or transrectally. Cytology of prostatic fluid or aspirates in BPH typically shows clusters of benign epithelial cells with uniform nuclei, occasional stromal cells, and no evidence of malignancy. In cases of prostatitis, there may be numerous neutrophils and bacteria. Histopathological examination of prostatic biopsies is the gold standard for diagnosis. In BPH, histology reveals hyperplasia of both glandular and stromal elements, with an increased number of acini, papillary projections, and cystic dilation. The epithelial cells are well-differentiated and lack atypia. There is often a mild inflammatory infiltrate. Special stains may be used to differentiate BPH from prostatic adenocarcinoma, which shows marked cellular atypia, invasion of the capsule, and loss of normal architecture. Immunohistochemistry for markers such as cytokeratin and vimentin may be helpful in challenging cases. Biopsy can be obtained via ultrasound-guided core biopsy, transrectal biopsy, or surgical biopsy. The risk of complications such as hemorrhage or infection is low but should be considered.

Treatment of benign prostatic hyperplasia depends on the severity of clinical signs and the desire to preserve fertility. For dogs with mild or no clinical signs, no treatment may be necessary, but regular monitoring is recommended. Medical management is the first-line therapy for dogs that are not intended for breeding. Castration (orchidectomy) is the most effective and definitive treatment, leading to a reduction in prostatic size by up to 50% within 3-4 weeks and complete resolution of clinical signs in most cases. Castration is a simple surgical procedure that can be performed routinely. For dogs that are intended for breeding, medical therapy with anti-androgens is preferred. Finasteride, a 5-alpha-reductase inhibitor, is commonly used at a dosage of 0.1-0.5 mg/kg orally once daily, and it reduces prostatic size without affecting fertility. Other options include osaterone acetate, an anti-androgen, at a dosage of 0.25-0.5 mg/kg orally once daily for 7 days, repeated as needed. These medications can be used long-term but may have side effects such as decreased libido. In cases of severe clinical signs or complications such as prostatic cysts or abscesses, surgical intervention may be required. Surgical options include prostatic omentalization, which is used for cysts and abscesses, and partial or total prostatectomy, which is reserved for neoplasia or severe disease. Prostatic omentalization involves draining the cyst or abscess and suturing the omentum into the cavity to promote drainage and healing. Total prostatectomy is associated with high morbidity, including urinary incontinence, and is rarely performed. Postoperative care includes pain management, antimicrobial therapy if infection is present, and monitoring for complications.

The prognosis for benign prostatic hyperplasia is excellent with appropriate treatment. Castration results in rapid involution of the prostate and resolution of clinical signs in the vast majority of dogs. Medical therapy with finasteride or osaterone acetate is also effective, with clinical improvement seen within 1-2 weeks and maximal reduction in prostatic size by 3 months. The prognosis is guarded if complications such as prostatitis, abscessation, or cyst formation are present, as these may require more aggressive intervention. Prostatic abscesses carry a mortality rate of up to 20% even with treatment. Prostatic neoplasia, which must be ruled out, has a poor prognosis, with a median survival time of less than 6 months. Overall, the long-term prognosis for uncomplicated BPH is excellent, and most dogs return to normal urinary and fecal function. Recurrence is unlikely after castration, but medical therapy may require ongoing administration. Regular follow-up is recommended to monitor for recurrence or complications.

Follow-up for benign prostatic hyperplasia depends on the treatment modality. After castration, dogs should be re-examined in 2-4 weeks to assess prostatic size and resolution of clinical signs. A repeat ultrasound may be performed to document reduction in prostatic volume. For dogs on medical therapy, re-evaluation is recommended at 1 month and then every 3-6 months to assess response and adjust dosage if needed. Prostatic size should be measured via ultrasound, and clinical signs should be monitored. If surgery was performed for complications such as cysts or abscesses, follow-up includes monitoring for recurrence, infection, and wound healing. Suture removal is typically 10-14 days postoperatively. Restricted activity is advised for 2-4 weeks after surgery to allow healing. Long-term monitoring includes regular urinalysis and culture to detect urinary tract infections, which are common in dogs with prostatic disease. Annual physical examinations and ultrasound are recommended for dogs with a history of BPH. Owners should be educated on the signs of recurrence or complications, such as dysuria, tenesmus, or fever.

Clinical pearls: 1) Digital rectal palpation is essential for evaluating the prostate; a symmetrically enlarged, non-painful prostate is suggestive of BPH. 2) Ultrasonography is the most valuable diagnostic tool; measure prostatic length, width, and height to calculate volume. 3) Castration is the treatment of choice for non-breeding dogs; it is curative and prevents recurrence. 4) Finasteride is a safe and effective option for breeding dogs; it does not affect semen quality. 5) Prostatic omentalization is a simple and effective technique for managing prostatic cysts and abscesses; it avoids the high morbidity of prostatectomy. 6) Always rule out prostatitis and neoplasia before diagnosing uncomplicated BPH. Pitfalls: 1) Failure to perform a thorough rectal exam may miss prostatic enlargement. 2) Relying solely on radiographs can underestimate prostatic size; ultrasound is superior. 3) Prescribing antibiotics without culture and sensitivity can lead to antimicrobial resistance. 4) Performing a prostatectomy for BPH is inappropriate and carries high morbidity; consider medical management or omentalization. 5) Overlooking concurrent urinary tract infections can lead to recurrent prostatitis. 6) In breeding dogs, avoid castration without owner consent; discuss medical options.

Perioperative pharmacological protocols for benign prostatic hyperplasia are primarily focused on pain management and antimicrobial prophylaxis if surgery is performed. For castration, a standard protocol includes: Preoperative: ampicillin 22 mg/kg IV or cefazolin 22 mg/kg IV at induction. Postoperative: carprofen 2.2 mg/kg PO q12h for 3-5 days, or meloxicam 0.2 mg/kg PO q24h for 3-5 days. For pain, buprenorphine 0.01-0.02 mg/kg IV or IM q8-12h may be used. For medical management of BPH, finasteride is administered at 0.1-0.5 mg/kg PO q24h. Osaterone acetate is given at 0.25-0.5 mg/kg PO q24h for 7 days, repeated as needed. If prostatitis is present, antimicrobial therapy should be based on culture and sensitivity; commonly used antibiotics include enrofloxacin 5-10 mg/kg PO q24h, or trimethoprim-sulfadiazine 15-30 mg/kg PO q12h, for 4-6 weeks. For dogs undergoing prostatic omentalization, perioperative antibiotics (e.g., cefazolin 22 mg/kg IV) are recommended, and postoperative analgesia with opioids (e.g., hydromorphone 0.05-0.1 mg/kg IV q4-6h) and NSAIDs as appropriate. Always adjust dosages for renal or hepatic impairment.

Evidence-based literature supports the efficacy of castration and medical therapy for benign prostatic hyperplasia. A landmark study by Krawiec and Heflin (1992) demonstrated that castration leads to a 50% reduction in prostatic volume within 3 weeks and resolution of clinical signs in 90% of dogs. Finasteride has been shown to reduce prostatic volume by 30-50% and improve clinical signs without affecting fertility (Sirinarumitr et al., 2001). Osaterone acetate has similar efficacy and is approved for use in Europe (Cauvin et al., 2004). For prostatic cysts and abscesses, prostatic omentalization has been reported to have a success rate of over 90% with low morbidity (White et al., 1997). A retrospective study by Basinger et al. (2003) compared omentalization to drainage and found omentalization superior in terms of recurrence and complications. The ACVS consensus statement on prostatic disease recommends castration as the first-line treatment for BPH, with medical therapy reserved for breeding dogs. Surgical intervention is indicated only for complications. Overall, the evidence strongly supports a conservative approach to BPH, with surgery reserved for specific indications.